Skip to main content
. Author manuscript; available in PMC: 2019 Jan 15.
Published in final edited form as: J Immunol. 2017 Dec 6;200(2):737–748. doi: 10.4049/jimmunol.1701229

Figure 1. RIPK1-deficient dendritic cells are more sensitive to necroptosis.

Figure 1

(A) Western blot depicting RIPK1 expression in CD11c+ enriched splenic DCs from CD11cCre and Ripk1DC KO mice. (B) RIPK1-deficient DCs are more susceptible to necroptosis. BMDCs were treated with 0.1 μM SMAC mimetics and 10 μM zVAD-fmk. Effects on cell viability were measured at 6 and 18h using Cell Titre Glo. N=6–8 independent samples. (C) Western blot depicting MLKL phosphorylation and total MLKL, RIPK1 and RIPK3 levels in BMDCs treated with SMAC mimetics and zVAD-fmk. Quantification of pMLKL relative to MLKL from 3 western blots is shown. (D) Number of splenic conventional and plasmacytoid DCs. (E) Number of DCs in the bone marrow. (F) Serum Flt3L levels in 4 week old mice. (G) DCs were incubated with OVA323–339 peptide for 1 hour then incubated with CFSE-labeled CD4+ OT-II T cells for 3 days. T cell proliferation was measured by flow cytometry. The percentage of proliferating CD4 T cells is shown from 5 independent samples. Error bars, means ± SEM. Unpaired two-tailed Student’s t test (B, D–G). * p<0.05.